SeekInCareTM
The first-in-class blood-based pan-cancer early detection service
When cancer is detected at the early stage, treatment is more effective and survival drastically improves. Yet ~50% of cancers are still only detected at an advanced stage.
SeekInCareTM is a CE-marked blood-based multi-omics pan-cancer screening test designed to identify cancer at its curable stage, enabling timely intervention to improve clinical outcomes.
Pan-cancer
Non-invasive
Early detection
Cancer localization
Highlights
- Utilizing AI-powered multi-omics platform to detect cancer signals through a blood test.
- By analyzing cell-free DNA (cfDNA) via shallow whole-genome sequencing (sWGS), it identifies genomic abnormalities (copy number aberration, fragment size, end motif, and oncogenic virus) and integrates 7 protein tumor markers (PTMs).
- Through machine learning, a cancer risk score (CRS) for early cancer screening is generated and the tissue of origin (TOO) is predicted when cancer signals are detected.
Indicated subjects
Adults aged 50+
Family history of cancer
Persistent unexplained symptoms
Chronic inflammatory diseases
Long-term exposure to cancer-causing environments
Unhealthy lifestyle
How it works
Customer order
Customers can place orders through SeekIn official website or local agents
Blood-draw
8 ml venous peripheral blood collected in cell-free DNA streck tube and can be stably stored at room temperature for 5 days
Testing
Detection by Roche cobas e411 instrument + next generation sequencing (NGS) platform
Reporting
The test results will be ready in about 10 workdays after your blood draw arrived at central lab
